Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
The Readout

Another Phase 3 disappointment & your guide to ASH and JPM

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Nov. 22, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for November 22, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Study finds same small rise in breast cancer risk…
Study finds same small rise in breast cancer risk in many forms of hormonal birth control
Experts weigh in on potential health hazards posed by…
Experts weigh in on potential health hazards posed by chemicals in Ohio train derailment
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories